Oncology
DA-4531
Unmet needs
- Limitations of current IO and anti-cancer therapies: Current IO therapies often show limited single-agent efficacy and low response rates, leading to a strong reliance on combination treatment strategies. In particular, there remains a high unmet need in poorly responsive patient populations such as aPD-1 refractory tumors and immune-cold tumors. In addition, there is an increasing demand for novel therapeutic strategies in indications with poor responsiveness to chemotherapy standard-of-care (SoC) treatments.
- Toxicity and patient selection challenges: Conventional IO approaches are associated with low response rates and toxicity driven by systemic immune activation. There is a growing need for predictive biomarker-based patient selection strategies and tumor microenvironment (TME)-selective immune activation approaches.
- Need for novel therapeutic mechanisms: There is a growing demand for the development of novel dual mechanism-based targets that simultaneously induce direct tumor growth suppression and immune activation. In particular, therapeutic approaches capable of achieving meaningful anti-tumor activity even as monotherapy are needed.
MoA (Mechanism of Action)
- Dual mechanism 1st: Immune activation Restores TBK1–IRF3–Type I IFN signaling to activate both innate and adaptive immune responses, thereby promoting anti-tumor immunity within the tumor microenvironment (TME).
- Dual mechanism 2nd: Direct anti-cancer effect Induces tumor cell growth suppression and cell death, resulting in direct anti-cancer activity independent of immune-mediated responses.
Key strengths
-
Through its dual mechanism-based mode of action, DA-4531 is expected to demonstrate strong anti-tumor
efficacy even as a monotherapy, with additional synergistic effects anticipated in combination settings.
-
By inducing tumor microenvironment (TME)-selective immune activation through a cancer cell-driven immune
activation mechanism, DA-4531 may potentially reduce systemic immune-related toxicity compared with
conventional IO therapies. -
In addition, predictive biomarker-based patient selection strategies may enable enhanced therapeutic
responsiveness and a differentiated efficacy profile.